SS-31 (Elamipretide) Safety Profile

Safety Overview

SS-31, also known as elamipretide or Bendavia, is not FDA-approved but is the most clinically advanced mitochondrial-targeting peptide. Developed by Stealth BioTherapeutics, it received FDA Fast Track designation for Barth syndrome (a rare mitochondrial disease).

Evidence Level: Moderate. Multiple Phase 2 and Phase 3 clinical trials with hundreds of participants. Safety profile is better characterized than most experimental peptides, though long-term data beyond 12 weeks is limited.

Known Side Effects (from Clinical Trials)

Side Effect	Frequency (vs. Placebo)	Severity
Injection site reactions	15-20%	Mild to moderate
Headache	8-12% (similar to placebo)	Mild
Dizziness	5-8%	Mild
Diarrhea	4-6%	Mild
Serious adverse events	No significant difference vs. placebo	N/A

Source: Phase 2/3 trials in Barth syndrome, heart failure, and primary mitochondrial myopathy (published 2019-2022).

Clinical Development History

Phase 3 Barth Syndrome Trial (TAZPOWER)

• Population: 12 patients with Barth syndrome (rare genetic mitochondrial disease)
• Duration: 12 weeks of treatment
• Route: Subcutaneous injection (40 mg daily)
• Primary endpoint: Did not meet statistical significance for 6-minute walk distance
• Safety: Well-tolerated with no serious treatment-related adverse events
• Status: Development for Barth syndrome discontinued (2020)

Other Indications Studied

• Heart failure with preserved ejection fraction (HFpEF): Phase 2 trial showed no significant benefit
• Primary mitochondrial myopathy: Phase 2/3 trials showed mixed results
• Acute myocardial infarction: Early-stage trials

Key Safety Advantages

Well-Characterized Mechanism

SS-31 is a tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) that selectively targets cardiolipin in the inner mitochondrial membrane. Unlike many experimental peptides, its mechanism has been extensively studied in preclinical models.

Clinical-Grade Manufacturing

Stealth BioTherapeutics produced elamipretide under GMP (Good Manufacturing Practice) standards for clinical trials, providing higher quality assurance than research-grade peptides.

No Major Safety Signals

Across multiple trials with subcutaneous administration up to 40 mg daily for 12 weeks, no serious safety concerns emerged. This is the best-documented safety profile of any mitochondrial peptide.

Limitations and Unknowns

Despite being the most studied mitochondrial peptide, gaps remain:

Unknown Factor	Status
Long-term safety (>12 weeks)	No published data
Effects in healthy individuals	All trials were in disease populations
Optimal dosing for longevity/performance	Not studied — trials used disease-specific dosing
Interactions with other medications	Limited pharmacokinetic data
Oral bioavailability	Poor (subcutaneous injection required)

Contraindications and Warnings

Based on clinical trial exclusion criteria:

• Pregnancy and breastfeeding (excluded from trials)
• Severe renal impairment (limited data)
• Active malignancy (theoretical mitochondrial effects on cancer cells)
• Children under 12 years (limited pediatric data, though some Barth patients were adolescents)

Product Quality Considerations

SS-31/elamipretide is not commercially available. Any products marketed as “SS-31” are from research chemical suppliers and are not pharmaceutical-grade. Risks include:

• Unknown purity and potency (clinical trials used proprietary formulation)
• Potential for peptide degradation (SS-31 contains modified amino acids)
• Lack of sterility testing for injectable products
• No quality control or batch consistency

Why Trials Failed to Show Efficacy

It’s important to note that safety and efficacy are separate questions. SS-31 appears safe in clinical trials but did not demonstrate strong efficacy for Barth syndrome or heart failure. Possible reasons:

• Dose or duration insufficient for measurable clinical benefit
• Disease endpoints too difficult to move in short trials
• Mitochondrial targeting alone may be insufficient for complex diseases
• Patient selection (disease severity, genetic heterogeneity)

This article is for informational purposes only. SS-31 (elamipretide) is not approved for human use. Consult a qualified healthcare provider before using any experimental peptide.